IGF1R and adrenal cortex carcinoma: Thus, with IGF1R being the main target of linsitinib, its low/absent expression in ACC might be one reason for the disappointing response rate in ACC patients (24) and pre-screening for IGF1R overexpression might then be useful to pre-select patients that may benefit from this treatment.